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Abstract 
The pharmacokinetics of levamisole in crucian carp, including the absorption, 
distribution, and clearance rates in different tissues, were studied at different 
temperatures and doses for the theoretical basis of proper usage and 
withdrawal time. The fish were divided into three groups denoted A, B and C. 
The A and B groups were treated once at a dosage of 5 mg/kg levamisole, at 
19 ± 1°C and 26 ± 1°C water temperature, respectively. The C group was 
treated at a dosage of 20 mg/kg levamisole at 19 ± 1°C water temperature. 
Then plasma, muscle, hepatopancreas, and kidney tissues samples were 
collected and pretreated, then measured using an ultra performance liquid 
chromatography-ultraviolet method. Plasma data were analyzed using DAS 
3.0 pharmacokinetics software. Total area under the curve (AUC0-t) and 
elimination half-life (t1/2z) had a negative correlation with water temperature, 
and a positive correlation with dosage. Apparent volume of distribution (Vz) 
and total clearance rate (CLz) was positively correlated with temperature, and 
a negatively correlated with dosage. Levamisole was absorbed quickly to 
reach its peak concentration. The drug concentration and residence time in 
hepatopancreal and kidney were considerably higher and longer respectively 
than in the muscle and plasma suggesting that the hepatopancreas and 
kidney may be important metabolic organs for levamisole. 
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Introduction 
As a common vermifuge of the imidazole and thiazole type (Cun et al., 2008), levamisole 
has been commonly used in animal husbandry for pigs, cows, and sheep because of its 
broad spectrum, high efficiency, low toxicity, and safety (Siegrid et al., 2003). The 
mechanism works to prevent reversion of fumaric acid to succinic acid by inhibiting the 
activity of the fumaric acid, which affects the process of the glycemic metabolism, to 
reduce the insect body ATP, which leads to body paralysis and death. Levamisole also 
plays a significant role in immunoregulation to strengthen immunity and increase animal 
growth. There have been many studies (Pereda et al., 2002; Cheng et al., 1991; Lin et 
al., 2003; Garcia et al., 1990; Galtier et al., 1983; Paulson & Feil, 1996; Xie et al., 1989; 
EI-Kholy & Kemppainen, 2005) on the pharmacokinetics of levamisole in terrestrial 
animals. It has been widely applied in the ornamental fish industry as an 
immunostimulant by improving phagocyte activity and neutrophilic granulocytes, 
stimulating the generation or secretion of lymphocytes, enhancing metabolic capability 
and lysozymes in the serum and inducing the generation of antibodies and complement 
proteins (Wang, 2018). Currently, more research reports concerning levamisole-induced 
immune enhancements and the bactericidal effects in fish have been published (Lipton et 
al., 2009; Siwicki, 1987; Xiang et al., 2002; Kajita et al., 1990; Huang et al., 2008; Wu 
et al., 1998) as well in sporozoa treatment (Chen, 2013), but less on levamisole 
pharmacokinetics in crucian carps. However, Levamisole hydrochloride is one of the 
effective drugs to treat myxosporiasis, and widely used in the prevention and cure of 
myxosporiasis in aquaculture industry (Liu & Wang, 2016; Wu et al. 2012 & Chen, 2013). 
The current study aims to investigate the pharmacokinetic parameters of levamisole in 
crucian carp and its absorption, distribution, clearance and residue (Syahidah et al., 
2015,) at different water temperatures and various doses. A second aim is to explore the 
effects of water temperature and dosage on the metabolic residue of levamisole in 
crucian carp, thus providing a theoretical basis for dosage plans and the withdrawal time 
of levamisole. 
    
Materials and Methods 
Fish.  
Healthy crucian carps carassius auratus gibelio ‘CAS No.3’, (weight 200 ± 15 g) were 
purchased from Changchun Jiutai seed multiplication farm and used for our experiments. 
To meet the test conditions, the fish were divided into individual aquariums, and kept in 
at a water temperature of 19 ± 1°C or 26 ± 1°C. The fish were not fed during the 
experiment. 
Solvent and solution preparation.  
Chromatographic pure ethyl acetate and methanol and analytic pure phosphoric acid, 
triethylamine, anhydrous sodium sulfate (dried for 4 hours at 650°C), hydrochloric acid, 
ammonium hydroxide, and boric acid were used for preparing the solutions or 
sample treatments. Ultrapure water was used as test water. Levamisole hydrochloride 
with a purity of 99.8% was provided by the National Control Institute of Veterinary 
Bioproducts and Pharmaceuticals. Levamisole hydrochloride with a purity of not less than 
98.0% was provided by Nanjing Nongmu Gaoke Biotechnology Co., Ltd.  
Preparation of standard solutions: levamisole hydrochloride standard was dissolved in 
methanol to a constant volume of 100 mL to produce a standard levamisole stock 
solution of 200 µg/mL. This was stored in a refrigerator, and away from light, at -18°C. 
Before use, the stock solution was diluted in methanol to prepare 0.1µg/mL, 0.5µg/mL, 
2.0µg/mL, 10µg/mL, 50µg/mL, 100µg/mL and 200µg/mL standard working solutions. 
6.18 g of boric acid was added as a buffer to 980 mL of water, then the pH was adjusted 
to a value of 9.0 with sodium hydroxide solution (10 M). Finally, water was added to 
reach a constant volume of 1000 mL.  
Oral administration and sample collection.  
The fish were divided into three test groups: group A, maintained at water 
temperature of 19 ± 1°C received one oral administration of levamisole at a rate of 5 
mg/kg body weight; group B, maintained at water temperature of 26 ± 1°C, received 
one oral administration of levamisole at 5 mg/kg body weight; group C, maintained at 
water temperature of 19 ± 1°C, received one oral administration of levamisole at 20 
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mg/kg body weight. The drug was administered orally to the fish foregut, and if no 
regurgitation occurred, the fish was used in the experiment. Six fish were taken at the 
following time points: 0.17, 0.5, 0.75, 1, 2, 4, 6, 8, 16, 24, 48, 72 and 144 hours after 
oral administration. Blood samples were obtained from the caudal vein and placed in a 
centrifuge tube with 1% heparin and centrifuged. The plasma supernatant was obtained. 
After blood was drawn, the fish were sacrificed and the muscle from two sides of the fish 
back bone, hepatopancreas, and kidney were excised, and all samples were stored away 
from light at -20°C until analysis.  
Pre-treatment of levamisole residues in plasma.  
Plasma samples were accurately absorbed and added to 15 mL centrifuge tubes. 
Boric acid buffer (1 mL; pH = 9) was added and then 10 mL of ethyl acetate was added. 
The centrifuge tube was vortexed for 2 min and centrifuged at 4000 rpm for 5 min. The 
supernatant was transferred to a vacuum tube of a BUCHI 48-digit multivapor. Ethyl 
acetate was added to the centrifuge tube, and the operation was repeated. The extracted 
solutions were combined, using a BUCHI 48-digit multivapor to dry the samples at 45-
55°C. Methanol (200 µL) which had dried under vaporization was added to the vacuum 
tube and then oscillated to dissolve the sample. The samples were then analyzed using a 
UPLC chromatographic instrument after filtration using a 0.22 μm filter screen.  
Pre-treatment method of levamisole residue in muscle, hepatopancreas, and kidney. 
This included the following three steps.  
(1) Extract: 5.00 g of sample was placed in a 50 mL centrifuge tube. Anhydrous 
sodium sulfate (5 g) was then added and mixed evenly. Boric acid buffer (1 mL; pH = 9) 
was then added into the centrifuge tube and vortexed for 2 min so the sample tissues 
were fully in contact with the buffer (Zeng, et al., 2010). 15 mL of ethyl acetate was 
added and vortexed for 2 min to form a paste with the tissue sample. The samples were 
then ultrasonicated for 10 min and centrifuged for 10 min at a speed of 4000 rpm. The 
organic phase was transferred into a 250 mL separatory funnel and 10 mL of ethyl 
acetate was added to the centrifuge tube. The operation was repeated once more to 
extract the remaining residues in the centrifuge tube. Then the extracts were combined 
with the above 250 mL in a funnel.  
(2) Liquid-liquid extraction: 15 mL of 0.1 M hydrochloric acid solution was added to 
the extract and oscillated for 2~3 min to permit static settlement. The lower layer was 
removed to form a standby solution.  
(3) Solid phase extraction: 3 mL of methanol and 3 mL of 0.1 M hydrochloric acid 
were added for activation of the mixed cation solid phase extraction column of Waters 
Oasis MCX. The standby solution in step (2) was passed through the column. The effluent 
was removed, and the column washed with 3 mL of water and 3 mL of methanol and 
blow dried. It was then eluted with 2 mL of methanol containing 4% ammonia water. The 
eluent was collected into a 2 mL glass centrifuge with scale, and then analyzed by UPLC 
after filtering with 0.22-μm membrane filter.  
Data analysis and liquid phase chromatographic conditions  
After pretreatment, all samples after pretreatment (plasma, muscle, viscus tissues 
and kidneys) were analyzed with an ultra-performance liquid chromatographic 
instrument-ultraviolet detector (Waters ACQUITY UPLC-UV) to obtain essential data. A 
Waters BEH C18 (1.7 µm, 50×2.1 mm) was used as the chromatographic column, and the 
column temperature was maintained at 35°C. The mobile phase: 0.05 M, the ratio of 
phosphoric acid (adjust pH value of triethylamine to 7.0) to acetonitrile was 85:15 (V/V). 
The flow rate was 0.4 mL/min. The sample volume was 5 µL. The UV detection wave 
length was 214 nm. The results were measured by internal standard method of 
chromatographic and the data were processed through SPSS software. The 
pharmacokinetic parameters and model fitting for the essential data were assessed using 
DAS 3.0 software. 
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Results 
Evaluation of sample test method  
The method used here produced a clear levamisole peak. The peaks corresponding to 
plasma, muscle, hepatopancreas, and kidney impurities were well separated from the 
standard peak and the substance chromatographic peak in the standard sample 
spectrogram was spiked and symmetric. A standard sample spectrogram and the blank 
spectrogram can be seen in Fig.1.  
 
The levamisole detection working solutions were 0.1~200μg/mL, the regression 
equation was Y=7.75e+004X+1.95e+004 with a correlation coefficient of R2 = 0.9999, 
where Y represented the chromatographic peak area and X represented the mass 
concentration of levamisole. The baseline noise of each blank tissue sample within the 
retention time of levamisole was obtained using the above analysis conditions. A triple 
signal-to-noise ratio was adopted as the qualitative detection limit. A decuple signal-to-
noise ratio was adopted as the quantitative detection limit. The qualitative detection limit 
of levamisole in plasma was 0.01 μg/mL, and the quantitative detection limit was 0.03 
μg/mL. The qualitative detection limit of levamisole in other tissues was 2 μg/kg, and the 
quantitative detection limit was 6 μg/kg. 
Accuracy and precision were expressed using the recovery ratio and variable 
coefficient, respectively. The concentration of levamisole added to plasma was 0.03 
μg/mL, 0.10 μg/mL or 0.30 μg/mL; the concentration of levamisole hydrochloride added 
to muscle, hepatopancreas, and kidney was 6 μg/kg, 20 μg/kg and 60 μg/kg, and the 
samples were tested in parallel continuously for 7 days. The recovery ratio ranged 
between 70% and 105%, and the variable coefficients were below 10%.  
Pharmacokinetic properties of levamisole in crucian carp 
Pharmacokinetic parameters were assessed using a non-compartmental statistical 
moment parameters analysis on the concentration of levamisole in plasma in the three 
test groups using the DAS 3.0 pharmacokinetics software. The pharmacokinetic 
parameters are shown in Table 1 and a comparison diagram of a concentration-time 
curves in plasma are shown in Fig. 2a. 
Table 1: Pharmacokinetic parameters of levamisole following oral administration to carp at different water 
temperatures or doses. 
 Group A Group B Group C 
Dose (mg/kg) 5 5 20 
Water temperature(°C) 19 ± 1 26 ± 1 19 ± 1 
Area under the curve AUC(0-t) (mg/L/h) 5.279 3.013 44.9 
Treminal elimination half-life t1/2z (h) 9.927 7.051 16.559 
Time to Peak Tmax(h) 0.75 0.5 1 
Measured maximal concentration Cmax (mg/L) 0.785 0.987 3.965 
Apparent volume of distribution Vz (L/kg) 9.467 16.884 2.661 
Clearance CLz(L/h/kg) 0.947 1.659 0.111 
 
Note: for group A, water temperature was maintained at 19 ± 1°C, levamisole was administered once orally at 
5 mg/kg; for group B, water temperature was t 26 ± 1°C, levamisole was administered once orally at 5 mg/kg; 
for group C, water temperature was  19 ± 1°C, levamisole was administered once orally at 20 mg/kg. This is 
true for all following Figures. 
 
 
Fig. 1. The blank and spiked 
standard chromatogram of 
muscle, hepatopancreas and 
plasma samples from crucian 
carp. 
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Absorption and distribution of levamisole in carp 
Fig. 2b, 2c and 2d demonstrate the concentration-time curves of levamisole in muscle, 
hepatopancreas and kidney respectively. 
In all three treatment groups, levamisole concentrations in muscle tissues increased 
first and then decreased with time after administration (Fig. 2b). In group B at a high 
temperature, levamisole concentrations reached their peak of 0.91 mg/kg at a time of 
0.5 h; in group A, levamisole concentrations reached their peak of 0.66 mg/kg at a time 
of 2 h; in group C, levamisole concentrations reached their peak last at a time of 4 h 
under the maximum dose, but with a peak concentration of 4.25 mg/kg.   
Fig. 2. Concentrations of 
levamisole in plasma (a), muscle 
tissues (b),  
hepatopancreal tissues (c), 
kidney tissues (d),  
orally-administered at different 
water temperatures or various 
doses. 
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In all three test groups, levamisole concentrations in the hepatopancreas reached 
their peak rapidly (0.5 h) and then decreased with increasing time after administration 
(Fig. 2c). Group C received the highest dose, and concentrations peaked at 44.47 mg/kg; 
in group B, concentrations peaked at 11.19 mg/kg; in group A, concentrations peaked at 
8.34 mg/kg. This result shows that high temperature contributes to an improvement in 
the absorption efficiency of levamisole in the hepatopancreas.  
In all three test groups, the change in the concentration of levamisole in the kidney 
over time was almost the same as that in muscle (Fig. 2d). Group B at high temperature, 
first reached a peak levamisole concentration of 5.90 mg/kg at a time of 0.5 h; group A 
reached a peak levamisole concentration of 4.15 mg/kg at a time of 1 h; group C 
received the highest dose, and concentrations peaked at 23.99 mg/kg at a time of 2 h. 
 
Discussion 
Comparison of pharmacokinetic parameters of levamisole in carp plasma 
With the same dose of 5 mg/kg, administered under different water temperatures, a non-
compartmental parameter analysis based on statistical moment theory using the 
concentration-time data of levamisole in carp plasma was performed. In the low-
temperature group A at 19 ± 1°C and the high-temperature group B at 26 ± 1°C, the 
peak time Tmax (0.5 h) in group B was slightly shorter than that (0.75 h) in group A. The 
peak concentration Cmax of 0.987 mg/L in group B was higher than that of 0.785 mg/L in 
group A, which indicates that raising the water temperature can accelerate drug 
absorption. The elimination half-life t1/2z of 7.051 h in group B was shorter than that of 
9.927 h in group A, which indicates that raising the water temperature also helps drug 
metabolism and elimination, to shorten the elimination half-life of a drug. The area under 
the concentration-time curve during administration AUC of 3.013 mg/L*h in group B was 
less than that of 5.279 mg/L*h in group A, demonstrating a negative correlation with 
water temperature. The apparent volume of distribution Vz indicates the degree of 
distribution of a drug, whereby the greater the value of Vz, the wider it is distributed. The 
Vz of 16.884 L/kg in group B was higher than that of 9.467 L/kg in group A. The total 
clearance rate CLz of 1.695 L/h/kg in group B was higher than that of 0.947 L/h/kg in 
group A, which indicates that Vz and CLz have a positive correlation with temperature. In 
other words, as the water temperature rises, levamisole could more easily penetrate 
tissues and become distributed. Moreover, the drug clearance rate through the blood or 
plasma was also increased.  
The dose is respectively 5 mg/kg (A) and 20 mg/kg (C) at a water temperature of 19 
± 1°C, a non-compartmental parameter analysis was performed based on statistical 
moment theory using the concentration-time data of levamisole in carp plasma. The time 
to peak concentration of 1 h in group C was later than that of 0.75 h in group A, and the 
peak concentration Cmax of 3.965 mg/L in group C was higher than that of 0.785 mg/L in 
group A, which indicates that, as the dose increased, the time to peak concentration was 
extended, and the peak concentration increased. The elimination half-life t1/2z of 16.559 h 
in group C was higher than that of 9.927 h in group A, which indicates that as the dose 
increased, the elimination half-life was prolonged. The AUC of 5.279 mg/L*h in group A 
was less than that of 44.9 mg/L*h in group C, and therefore demonstrated a positive 
correlation with dose. The apparent volume of distribution Vz of 2.661 L/kg in group C 
was less than that of 9.467 L/kg in group A. The total clearance rate CLz of 0.111 L/h/kg 
was lower than that of 0.947 L/h/kg in group A. In other words, Vz and CLz had a 
negative correlation with dose, which indicates that as the dose increased the amount by 
which levamisole penetrates tissues did not increased correspondingly. 
Distribution and elimination of levamisole in each tissue 
The results of the current study showed that the concentration of levamisole in fish 
plasma, muscle, hepatopancreas, and kidney increased at first and then decreased until 
elimination. The concentration in the hepatopancreas peaked first, and then in the 
plasma, kidney, and muscle. The peak concentration in the hepatopancreas was the 
highest, followed by the kidney and muscle. The results demonstrate that after oral 
administration levamisole can be absorbed rapidly and is distributed in tissues under 
different conditions.    
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At different water temperatures, the time to achieving peak levamisole concentration 
in each tissue in group B was shorter than that of the corresponding tissues in group A, 
and the peak concentration was 1.26~1.34 times of that in group A. Levamisole was not 
detected in muscle and kidney at 72 h in group B, and the concentration of levamisole in 
the hepatopancreas was lower than the detection limit at 144 h. In group A, the 
concentration of levamisole in muscle and kidney was lower than the detection limit at 
144 h, and at this time the concentration of levamisole in the hepatopancreas was still 
0.084 mg/kg. These results indicate that the higher the water temperature the faster the 
levamisole was absorbed, and the greater the increase in absorption efficiency. 
Meanwhile, high temperature also helped in metabolizing and eliminating the drug in 
each tissue and reducing residues.    
At the same water temperature, the dose for group C was four times more than that 
for group A. The time to achieving peak concentration in group C was longer than that of 
group A, except in the hepatopancreas. The peak concentration in group C was 
2.97~5.44 times higher than that in group A, and at the same time point, the drug 
concentration in each tissue in group C was higher than that in group A, particularly the 
drug concentration in the muscle tissues, which was far higher than that in group A. The 
concentration in the hepatopancreas was far higher than that in the muscle.  
In all three treatment groups, the concentration of levamisole in the hepatopancreas 
at its peak was 10.5~12.6 times more than that in the muscle, and 1.8~2.0 times more 
than that in the kidney. The residence time of levamisole was longest in the 
hepatopancreas, and therefore the hepatopancreas has been identified as the residual 
target tissue of levamisole in carp. In addition, the drug concentration in the kidney was 
far higher than in the muscle and plasma, and only lower than that in the 
hepatopancreas. Therefore, the kidney has also been identified as a major organ for 
metabolizing levamisole. 
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